Report overview
Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.
This report aims to provide a comprehensive presentation of the global market for Neuromyelitis Optic Spectrum Disorder Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuromyelitis Optic Spectrum Disorder Drugs. This report contains market size and forecasts of Neuromyelitis Optic Spectrum Disorder Drugs in global, including the following market information:
Global Neuromyelitis Optic Spectrum Disorder Drugs Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global Neuromyelitis Optic Spectrum Disorder Drugs Market Sales, 2018-2023, 2024-2030, (Kiloton)
Global top five Neuromyelitis Optic Spectrum Disorder Drugs companies in 2022 (%)
The global Neuromyelitis Optic Spectrum Disorder Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Glucocorticoids Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Neuromyelitis Optic Spectrum Disorder Drugs include Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork and Baxter, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Neuromyelitis Optic Spectrum Disorder Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Neuromyelitis Optic Spectrum Disorder Drugs Market, by Type, 2018-2023, 2024-2030 ($ Millions) & (Kiloton)
Global Neuromyelitis Optic Spectrum Disorder Drugs Market Segment Percentages, by Type, 2022 (%)
Glucocorticoids
Immunotherapies
Other
Global Neuromyelitis Optic Spectrum Disorder Drugs Market, by Application, 2018-2023, 2024-2030 ($ Millions) & (Kiloton)
Global Neuromyelitis Optic Spectrum Disorder Drugs Market Segment Percentages, by Application, 2022 (%)
Acute Attack
Remission Prophylactic Treatment
Global Neuromyelitis Optic Spectrum Disorder Drugs Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions) & (Kiloton)
Global Neuromyelitis Optic Spectrum Disorder Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Neuromyelitis Optic Spectrum Disorder Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Neuromyelitis Optic Spectrum Disorder Drugs revenues share in global market, 2022 (%)
Key companies Neuromyelitis Optic Spectrum Disorder Drugs sales in global market, 2018-2023 (Estimated), (Kiloton)
Key companies Neuromyelitis Optic Spectrum Disorder Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Fresenius
Teva
Sandoz
Intas
Gyjtrs
NANG KUANG
Tianjin Kingyork
Baxter
CSL
Grifols
Octapharma
CBOP
Outline of Major Chapters:
Chapter 1: Introduces the definition of Neuromyelitis Optic Spectrum Disorder Drugs, market overview.
Chapter 2: Global Neuromyelitis Optic Spectrum Disorder Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Neuromyelitis Optic Spectrum Disorder Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Neuromyelitis Optic Spectrum Disorder Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Neuromyelitis Optic Spectrum Disorder Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
